← Markets

Regeneron Pharmaceuticals, Inc.

REGN · NASDAQ

Market closed$676.69$-2.25 (-0.33%)After hours $674.00 · -0.40%

Key statistics

Previous close$678.94
Open$674.63
Day high$690.66
Day low$672.31
52-week high$821.11
52-week low$541.00
Market cap69.71B
Volume623.29K
Average volume1.00M
P/E ratio14.83
Forward P/E—
EPS45.63
Dividend yield+0.54%

Market context

Why it moved

REGN edged lower as multiple class action lawsuits filed against Regeneron continued to weigh on investor sentiment, alleging the company misled investors about the viability of its Phase III Fianlimab-Libtayo study, which had previously failed to reach statistical significance on its primary endpoint.

BajajfinservMorningstarNatlawreviewGovCor

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Regeneron closed slightly lower amid a class action lawsuit alleging the company misled investors about its Phase III fianlimab-Libtayo melanoma trial, which failed to reach statistical significance for progression-free survival improvement against Keytruda in May. Despite posting strong Q1 revenues of $3.61 billion (up 19% YoY, beating estimates by 3.8%), shares are down ~9.6% since reporting as the trial setback overshadows fundamentals — even as broader biotech peers have rallied and analyst consensus remains bullish with an average price target near $875.

-0.3314

July 17, 2026Regeneron shares rose roughly 2% on July 16, outperforming a broadly mixed market where the S&P 500 slipped 0.4% amid renewed pressure on AI-linked tech stocks. The healthcare sector provided a supportive backdrop, lifted by UnitedHealth Group's strong Q2 earnings beat and raised full-year guidance, which boosted sentiment across the space. Still, Regeneron remains under a cloud from its May fianlimab-Libtayo Phase 3 melanoma trial failure — which triggered a nearly 10% single-day decline in May — and a subsequent securities class action lawsuit alleging the company misled investors about the trial's viability. Despite these headwinds, Q1 revenue of $3.61B beat estimates by 3.8%, and the consensus analyst price target remains well above current levels.

2.1808

July 16, 2026Regeneron Pharmaceuticals closed modestly higher, outperforming the broader healthcare sector ETF (XLV) which ended relatively flat, as investors responded to a favorable macro backdrop — softer-than-expected June CPI data eased rate hike fears and boosted sentiment across biopharma names. The gain comes despite lingering overhang from a May clinical setback, when the fianlimab/Libtayo combination failed to beat Merck's Keytruda in a pivotal melanoma trial; however, with 22 of 29 analysts maintaining Buy ratings and an average price target of ~$875, institutional conviction remains firm. After-hours trading extended gains to ~$672, suggesting continued investor confidence heading into Q2 earnings season.

1.2696

July 14, 2026Regeneron closed essentially flat amid a broader market selloff driven by escalating U.S.-Iran tensions, though multiple analyst reiterations of Buy ratings kept sentiment constructive. Cantor Fitzgerald reiterated its Overweight rating with a $750 price target, while BofA Securities maintained its Buy rating but trimmed its target to $856 from $860, citing Eylea HD/SD and Dupixent performance relative to consensus. The stock is trading modestly higher in after-hours, recovering some ground as investors weigh the pipeline narrative—including the May fianlimab/Libtayo melanoma trial setback—against Dupixent's continued strength and the company's recently secured drug pricing deal with the White House.

-0.2152

July 11, 2026Regeneron Pharmaceuticals closed modestly lower, edging down amid a broader healthcare sector pullback as the XLV health sector ETF also declined on the day. Sentiment around REGN remains cautious following a wave of analyst price target cuts — Morgan Stanley lowered its target to $730, RBC Capital trimmed to $696, and HSBC cut to $800 from $990 — as the Street recalibrates after the company's failed Phase 3 fianlimab/LAG-3 melanoma trial earlier this year. On a positive note, Piper Sandler maintained an Overweight rating with a $854 target, and investors have been looking past a ~$127M Q2 in-process R&D charge tied to licensing activity, focusing instead on cemdisiran's FDA Priority Review for myasthenia gravis with a decision expected in November 2026.

-0.5135

July 10, 2026Regeneron Pharmaceuticals edged higher, outperforming a mixed broader market as investors continued to look past a disclosed ~$127 million Q2 acquired in-process R&D charge, viewing it as a pipeline investment signal rather than core business weakness. The stock is benefiting from a strong sector tailwind — healthcare has been the top-performing S&P 500 sector for two consecutive weeks — alongside Jim Cramer's widely-noted call that biotech is "the hottest group in the market" amid expectations for an M&A surge under the current regulatory backdrop. Analyst sentiment remains constructive, with a median Street price target of $850 and Piper Sandler maintaining an Overweight rating.

0.7648

July 9, 2026Regeneron closed down nearly 2% as broader market risk-off sentiment — driven by the collapse of the U.S.-Iran ceasefire framework and a surge in oil prices — weighed on equities broadly, with the S&P 500 and healthcare sector ETF XLV also pulling back. The decline follows a strong 3%+ rally the prior session, when investors looked past a disclosed $127 million Q2 IPR&D charge tied to collaboration deals, focusing instead on pipeline progress including regulatory submissions for cemdisiran in myasthenia gravis. Morgan Stanley trimmed its price target to $730 from $788 (Equalweight), though broader analyst consensus remains constructive with a Moderate Buy rating and average target near $793, well above current levels.

-1.9742

July 8, 2026Regeneron Pharmaceuticals gained over 4% as investors looked past a disclosed $127 million Q2 acquired IPR&D charge — tied to collaboration and licensing deal payments — and instead focused on the company's pipeline momentum and M&A optionality. Jim Cramer highlighted Regeneron as a prime biotech M&A candidate, citing Dupixent's 33% global sales growth to $4.88 billion and a new $3 billion buyback authorization, while the healthcare sector (XLV) extended its recent winning streak near 52-week highs as a broader rotation out of technology continued.

4.0658

Simply Wall Street · July 17, 2026Regeneron (REGN) Stock Looks Discounted As It Holds A 24% GainBloomberg Law News · July 16, 2026Regeneron Investor Sues Over Cancer Drug Trial Miss, Stock DropsSimply Wall Street · May 31, 2026WHO Ebola Trial Puts Regeneron’s Maftivimab Platform In Investor FocusInvestor's Business Daily · May 18, 2026The Surprising Reason Regeneron Pharmaceuticals Just Dropped 10%
Benzinga · July 9, 2026Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $854
Mt Newswire · July 9, 2026Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $854 From $855
Mt Newswire · July 8, 2026Morgan Stanley Adjusts Price Target Regeneron Pharmaceuticals to $730 From $788, Maintains Equalweight Rating
Benzinga · July 7, 2026RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Lowers Price Target to $696
Mt Newswire · July 7, 2026RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $696 From $707, Maintains Sector Perform Rating
Benzinga · July 7, 2026Benchmark Upgrades Regeneron Pharmaceuticals to Buy, Announces $185 Price Target
Benzinga · July 6, 2026HSBC Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $880
Benzinga · July 6, 2026Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $750

Peers

S&P 500SPX · $7,457.69-1.01%Amgen Inc.AMGN · $366.29-1.42%Gilead Sciences, Inc.GILD · $134.28-1.48%Moderna, Inc.MRNA · $61.82-2.11%AbbVie Inc.ABBV · $254.49+0.04%Bristol-Myers Squibb CompanyBMY · $60.74+0.38%Vertex Pharmaceuticals IncorporatedVRTX · $485.65-0.08%Biogen Inc.BIIB · $205.99-1.40%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%argenx SEARGX · $860.55+0.30%Intellia Therapeutics, Inc.NTLA · $11.38-4.09%Royalty Pharma plcRPRX · $58.18-0.60%